Acute and repeated dose 28-day oral toxicity of poly(3-hydroxybutyrate- co -4-hydroxybutyrate) nanoparticles in Sprague-Dawley rats

Leong, Yin‐Hui; Isa, Anis Syaffini Mat; Moey, Chiew Erh Jacqueline; Utar, Zulkhurnain; Soon, Yong-Ing; Majid, Mohamed Isa Abd

doi:10.1016/j.yrtph.2018.03.011

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The histological study of the heart, kidney, spleen, lung and liver were performed as described previously ( Leong et al, 2018 ). Briefly, tissues were fixed in 10% paraformaldehyde and then embedded in paraffin wax after the samples were dehydrated in graded alcohol.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the Acute and Sub-Acute Oral Toxicity of Jaranol in Kunming Mice

Liu

Zhang²,

Liu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Jaranol has shown a wide range of pharmacological activities; however, no study has yet examined in vivo toxicity. The study aimed to investigate the oral acute and sub-acute toxicity of jaranol in mice.Methods: The acute toxicity was determined by a single oral dose of jaranol (2000 mg/kg). Therein animal behaviour and mortality rate were observed for 14 days. The jaranol (50, 100 and 200 mg/kg BW·d−1) was given by gavage for 28 days daily in the sub-acute study. The mouse body weight (BW), organ weight, food, water intake, biochemical, haematological parameters, and histopathology were studied in acute and sub-acute toxicity.Results: During the acute toxicity test, a single oral dose (2000 mg/kg) jaranol did not cause significant alteration in majority of the hematological indices. However, jaranol decreased the level of serum alanine aminotransferase and aspartate aminotransferase. Those results showed that the oral lethal dose 50 (LD50) of jaranol was higher than 2000 mg/kg BW, regardless of sex. In repeated daily oral doses (50, 100 and 200 mg/kg BW·d−1), no mortality was recorded in the various experimental groups. The jaranol reduced body weight gain (200 mg/kg BW·d−1), the relative spleen weight (all doses) and serum alanine aminotransferase activity (200 mg/kg BW·d−1). On the other hand, jaranol significantly elevated red blood cell count (100 and 200 mg/kg BW·d−1) and serum creatinine levels (200 mg/kg BW·d−1). Histological study revealed that spleen bleeding was identified in 200 mg/kg jaranol-treated mice.Conclusion: Jaranol was relatively safe in Kunming Mice when repetitively administered orally in small doses for a prolonged period of time. We recommend more chronic toxicity studies and clinical trials on jaranol to ensure that its use is free of potential toxicity to humans.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of the Acute and Sub-Acute Oral Toxicity of Jaranol in Kunming Mice

Liu

Zhang²,

Liu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…A weight of each organ was measured using weighing balance. An organ-to-final-body-weight ratio was calculated for each organ [ 20 ]. All the isolated organs were washed with saline and fixed in the 10 % neutral buffered formalin.…”

Section: Methodsmentioning

confidence: 99%

Acute and 28-days subacute toxicity studies of Gαq-RGS2 signaling inhibitor

Beladiya

Mehta

2021

Lab Anim Res

View full text Add to dashboard Cite

Background The aim of study was to evaluate the single oral dose and 28 day repeated oral administration toxicity profile of the synthetic compound Gαq-RGS2 signaling inhibitor, (1-(5-chloro-2-hydroxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1 H-1,2,4-triazol-5(4 H)-one) as per OECD guideline 425 (2008a) and 407 (2008b), respectively. Results In acute toxicity study, a single oral dose administration of Gαq-RGS2 signaling inhibitor did not show any mortality at doses of 5, 50, 300 and 2000 mg/kg within 24 h and 14 days. The treatment of Gαq-RGS2 signaling inhibitor at dose 10 and 100 mg/kg for 28 days did not show any mortality, significant changes in the increase of body weight, various organ damage markers, hematological parameters, relative organ/body weight ratio and microscopic anatomical texture of essential organs as compared to vehicle and normal control. Conclusions A single oral administration of Gαq-RGS2 signaling inhibitor up to dose of 2000 mg/kg in mice and repeated administration of Gαq-RGS2 signaling inhibitor at higher dose 100 mg/kg for 28 days in the rats is safe.

show abstract

“…As a biodegradable biopolyester, poly(3-hydroxy butyrate-co-4-hydroxybutyrate) (P(3HB-co-4HB)) has been widely applied in the fields of agriculture, fine chemicals, packaging [5,6], biology and tissue engineering owing to its outstanding biocompatibility, plasticity, toughness, and degradability [7,8]. However, P(3HB-co-4HB) lacks active functional groups.…”

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of poly(3-hydroxybutyrate-co-4-hydroxybutyrate)/pullulan-gelatin electrospun nanofibers with shell-core structure

et al. 2020

View full text Add to dashboard Cite

In this study, hydrophilic pullulan, which is favorable for cell adhesion, proliferation, and differentiation, was selected as a modifier for the preparation of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (P(3HB-co-4HB))/pullulan nanofibers via electrospinning to improve the biocompatibility of P(3HB-co-4HB) and increase the drug loading of composite fibers. Alkyl polyglycoside was used as the emulsifying agent to promote emulsification and stabilize the P(3HB-co-4HB)/pullulan composite solution. Drug-loading property of the nanofibers with a shell-core structure is increased because gelatin was not formed into fibers via electrospinning, thereby forming a stable drug-containing gelatin solution in the core layer. Finally, P(3HB-co-4HB)/pullulan-gelatin shell-core nanofibers were prepared. The intermolecular interaction, morphology, crystallization properties, mechanical properties, morphology, sustained release, and biocompatibility of composite nanofibers were characterized. Results show that the crystallization property of P(3HB-co-4HB)/pullulan composite nanofibers increases continuously with an increase in the pullulan content. As the pullulan content increases, the strain and stress of P(3HB-co-4HB)/pullulan nanofibers increase initially and decrease later. At the mass ratio of P(3HB-co-4HB) to pullulan of 10:2, P(3HB-co-4HB)/pullulan composite nanofibers exhibit a uniform morphology with an average diameter of 590 nm and porosity of 70.71%. At this mass ratio, the P(3HB-co-4HB)/pullulan-gelatin/drug shell-core structure, which sustained a release effect for more than 180 h, has potential applications as biomaterials without cytotoxicity.

show abstract

Acute and repeated dose 28-day oral toxicity of poly(3-hydroxybutyrate- co -4-hydroxybutyrate) nanoparticles in Sprague-Dawley rats

Cited by 6 publications

References 25 publications

Evaluation of the Acute and Sub-Acute Oral Toxicity of Jaranol in Kunming Mice

Evaluation of the Acute and Sub-Acute Oral Toxicity of Jaranol in Kunming Mice

Acute and 28-days subacute toxicity studies of Gαq-RGS2 signaling inhibitor

Preparation and characterization of poly(3-hydroxybutyrate-co-4-hydroxybutyrate)/pullulan-gelatin electrospun nanofibers with shell-core structure

Contact Info

Product

Resources

About